“…Liposome-delivered anticancer agents, such as doxorubicin, have been proved to reduce side effects (cardiotoxicity, gastrointestinal toxicity, stomatitis, hair loss, etc) while exhibiting superior performance or preserving efficacy in clinical studies and maintaining an extended period of therapeutic concentration. [11][12][13] Considerable efforts have been devoted to extend the lifetime and integrity of liposomes in the bloodstream to periods on the order of days, raising the successful rate of transportation to the target location, 14,15 but the liposomes interfere with the passive drug release efficiency upon arriving at the destination and reduce clinical efficacy. [16][17][18][19] An active triggered mechanism is required to facilitate sufficient liposome content release in situ for optimal treatment effects, [16][17][18][19][20][21] and a non-invasive or minimally invasive monitoring method is required to adjust the topical release kinetics tailored for each subject in vivo by detecting drug-induced bio-events, with the goal of achieving and extending the therapeutic dosage period without exceeding toxic levels.…”